These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30185395)

  • 1. Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects.
    Li X; Chen H; Niu J; Chen G; Shen G; Massetto B; Brainard DM; Zhu X; Zhang H; Ding Y
    Clin Ther; 2018 Sep; 40(9):1556-1566. PubMed ID: 30185395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS-331007 in Healthy Chinese Subjects.
    Shen Z; Zhu X; Zhang H; Chen H; Niu J; Chen G; Li X; Ding Y
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1073-1080. PubMed ID: 30900816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
    Li C; Li X; Zhu X; Zhang H; Shen G; Kersey K; Ding Y
    Clin Ther; 2020 Mar; 42(3):448-457. PubMed ID: 32115243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
    Mogalian E; Brainard DM; Osinusi A; Moorehead L; Murray B; Ling KHJ; Perry R; Curtis C; Lawitz E; Lasseter K; Marbury T; Mathias A
    Clin Pharmacokinet; 2018 Nov; 57(11):1449-1457. PubMed ID: 29520729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
    Schrezenmeier E; Hoffmann F; Jaeger C; Schrezenmeier J; Lisec J; Glander P; Algharably E; Kreutz R; Budde K; Duerr M; Halleck F
    Ther Drug Monit; 2019 Feb; 41(1):53-58. PubMed ID: 30422962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the pharmacokinetics and food intake effect of generic sofosbuvir in healthy Chinese subjects
.
    Li X; Liu Y; Xu B; Liu L; Li Y; Zhang P; Wang Y
    Int J Clin Pharmacol Ther; 2020 Apr; 58(4):230-241. PubMed ID: 32053101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
    Lawitz E; Poordad F; Gutierrez JA; Kakuda TN; Picchio G; Beets G; Vandevoorde A; Van Remoortere P; Jacquemyn B; Luo D; Ouwerkerk-Mahadevan S; Vijgen L; Van Eygen V; Beumont M
    J Viral Hepat; 2017 Apr; 24(4):287-294. PubMed ID: 27878906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
    Mizokami M; Yokosuka O; Takehara T; Sakamoto N; Korenaga M; Mochizuki H; Nakane K; Enomoto H; Ikeda F; Yanase M; Toyoda H; Genda T; Umemura T; Yatsuhashi H; Ide T; Toda N; Nirei K; Ueno Y; Nishigaki Y; Betular J; Gao B; Ishizaki A; Omote M; Mo H; Garrison K; Pang PS; Knox SJ; Symonds WT; McHutchison JG; Izumi N; Omata M
    Lancet Infect Dis; 2015 Jun; 15(6):645-53. PubMed ID: 25863559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.
    Kirby BJ; Symonds WT; Kearney BP; Mathias AA
    Clin Pharmacokinet; 2015 Jul; 54(7):677-90. PubMed ID: 25822283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
    King JR; Dutta S; Cohen D; Podsadecki TJ; Ding B; Awni WM; Menon RM
    Antimicrob Agents Chemother; 2016 Feb; 60(2):855-61. PubMed ID: 26596948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
    Rodriguez-Torres M; Lawitz E; Kowdley KV; Nelson DR; Dejesus E; McHutchison JG; Cornpropst MT; Mader M; Albanis E; Jiang D; Hebner CM; Symonds WT; Berrey MM; Lalezari J
    J Hepatol; 2013 Apr; 58(4):663-8. PubMed ID: 23183528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
    J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.
    German P; Mathias A; Brainard D; Kearney BP
    Clin Pharmacokinet; 2016 Nov; 55(11):1337-1351. PubMed ID: 27193156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
    Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L
    Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.
    Kakuda TN; McClure MW; Westland C; Vuong J; Homery MC; Poizat G; Viguerie L; Denot C; Patat A; Zhang Q; Hui J; Apelian D; Smith DB; Chanda SM; Fry J
    Pharmacol Res Perspect; 2018 Jun; 6(3):e00395. PubMed ID: 29736243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
    Borgia SM; Dearden J; Yoshida EM; Shafran SD; Brown A; Ben-Ari Z; Cramp ME; Cooper C; Foxton M; Rodriguez CF; Esteban R; Hyland R; Lu S; Kirby BJ; Meng A; Markova S; Dvory-Sobol H; Osinusi AO; Bruck R; Ampuero J; Ryder SD; Agarwal K; Fox R; Shaw D; Haider S; Willems B; Lurie Y; Calleja JL; Gane EJ
    J Hepatol; 2019 Oct; 71(4):660-665. PubMed ID: 31195062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
    Mogalian E; Stamm LM; Osinusi A; Brainard DM; Shen G; Ling KHJ; Mathias A
    Clin Infect Dis; 2018 Aug; 67(6):934-940. PubMed ID: 29522076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
    Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A phase II, single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of sofosbuvir combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection].
    Gao YH; Li GM; Jin QL; Zhao YR; Jia ZS; Mao XR; Yang YF; Shang J; Wang GC; Xie W; Wu SM; Zhang MX; Hou JL; Li DL; Nan YM; Guan YJ; Zhu CX; Yuan YZ; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):352-357. PubMed ID: 31177659
    [No Abstract]   [Full Text] [Related]  

  • 20. Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.
    Miller MM
    Am J Health Syst Pharm; 2017 Jul; 74(14):1045-1052. PubMed ID: 28687550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.